Special issue of the Journal of Neuromuscular Diseases is devoted to the Treatabolome, designed to shorten diagnosis-to-treatment time for patients with rare diseases

In 2019, as part of the European Solve-RD project, Hanns Lochmüller, Gisèle Bonne and Rachel Thompson launched the Treatabolome, an initiative designed to extract details of effective treatments for rare diseases from the scientific literature and make them accessible through an online database that aims to allow patients to receive the right treatment for their condition as soon as they receive a genetic diagnosis.

The process of extracting reliable treatment information from scientific publications begins with a systematic review of the literature for each disease area to ensure that all the published information is captured. The Lochmüller Lab’s original systematic review of congenital myasthenic syndromes provided a comprehensive overview of the treatments available for these rare but often highly treatable diseases, which are one of our lab’s main focus areas.

This month, an open-access special issue of the Journal of Neuromuscular Diseases dedicated to the Treatabolome has been published. It includes six systematic reviews contributed by experts on rare neurological disorders, summarising the literature on each disease group and linking treatments with genotype and causative variants. Thanks to the team at CNAG in Barcelona behind the RD-Connect Genome-Phenome Analysis Platform, the data is also being transformed into an online database to be launched later this summer, which is intended to reduce treatment delays for patients with rare diseases by directly linking diagnosis and treatment information.

The special issue also includes a systematic review on the metabolic myopathies from our lab with Alex Manta, Sally Spendiff, Hanns Lochmüller and Rachel Thompson as co-authors.

You can find Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a ‘Treatabolome’  here.

Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a ‘Treatabolome’.
Manta A, Spendiff S, Lochmüller H, Thompson R.
J Neuromuscul Dis. 2021;8(3):401-417.
doi: 10.3233/JND-200621.
PMID: 33720849

 

Access the special issue of the Journal of Neuromuscular Diseases here.

Read the press release about the Treatabolome special issue here.

1by1treatabolome

Read next...

Text reading: Solve-RD publication: Solve-RD flagship publication: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses. Photos of Dr Kiran Polavarapu, Dr Rachel Thompson, Dr Hanns Lochmüller.

Solve-RD flagship publication in Nature Medicine: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses

Patients and families with rare disorders often remain without a genetic diagnosis despite modern advances in diagnostic testing. Due to the rarity and global distribution...
New publication: Identifies Novel ATP2A2 Variant as Genetic Cause of Dominant Rhabdomyolysis . Author's photos on the right, diagram from paper underneath title.

New Lab Publication Identifies Novel ATP2A2 Variant as Genetic Cause of Dominant Rhabdomyolysis

Rhabdomyolysis is an acute failure of cellular homeostasis characterized by acute skeletal muscle damage triggered by trauma, infection, drugs, or strenuous exercise. Recurrent rhabdomyolysis is...
New lab publication on riboflavin transporter deficiency model

New Publication: Development of a riboflavin-responsive model of riboflavin transporter deficiency in zebrafish

Riboflavin transporter deficiency (RTD) is a rare genetic disorder in children, characterised by progressive sensorimotor and cranial neuronopathy caused by mutations in riboflavin transporter protein-encoding...
Congratulations CNMD Ottawa on 25 years of neuromuscular research. Photo of all former and current directors of the Centre.

uOttawa Eric Poulin Centre for Neuromuscular Disease Celebrates 25 Years of Neuromuscular Research

New co-directors Dr Mireille Khacho and Dr Hanns Lochmüller begin their tenure On November 25th the University of Ottawa Eric Poulin Centre for Neuromuscular Disease...
Clinical trial update - Canadian Patient First in the World to Receive Trial Drug in Argenx DOK7-CMS Study

Canadian Patient Dosed in Argenx DOK7-CMS Study

Our clinical research team at the NeuroMuscular centre of The Ottawa Hospital is excited to share that a Canadian patient affected by DOK-7 Congenital Myasthenic...
New lab publication - Brain malformations and seizures by impaired chaperonin function of TRiC

New Publication: Brain malformations and seizures by impaired chaperonin function of TRiC

We are excited to share a new publication from our research team! The study “Brain malformations and seizures by impaired chaperonin function of TRiC” uncovers...